Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Investor webinar reminder and presentation

November 4, 2026

Notification of cessation of securities - NUZ

November 1, 2026

Withdrawal of Resolution 4 from Notice of AGM

November 1, 2026

Redemption of all remaining Obsidian convertible notes

November 1, 2026

Redemption of all remaining Obsidian convertible notes

November 1, 2026

Proposed issue of securities - NUZ

November 1, 2026

Proposed issue of securities - NUZ

November 1, 2026

Firm commitments to raise A$4.3m and announcement of SPP

November 1, 2026

Firm commitments to raise A$4.3m and announcement of SPP

November 1, 2026

Trading Halt

October 28, 2026

Trading Halt

October 28, 2026

Appendix 4C & Quarterly Update

October 27, 2026

Appendix 4C & Quarterly Update

October 27, 2026

Notice of Annual General Meeting/Proxy Form

October 26, 2026

Change of AGM Date

October 22, 2026

Notification of cessation of securities - NUZ

October 13, 2026

Updated Investor Presentation and Webinar Reminder

October 6, 2026

FDA Type C Feedback, HEALEY trial potentially registrational

October 5, 2026

Dr Chris Bremer commences as Neurizon CEO

September 30, 2026

Change of Director's Interest Notice

September 16, 2026

Notification of cessation of securities - NUZ

September 15, 2026

Neurizon Announces Partial Redemption of Convertible Notes

September 9, 2026

Application for quotation of securities - NUZ

September 9, 2026

NIH funds Expanded Access Program for NUZ-001 in ALS

September 8, 2026

Neurizon Appoints Chief Executive Officer

September 6, 2026

Application for quotation of securities - NUZ

August 25, 2026

Appendix 4E and 2026 Annual Report

August 25, 2026

Appendix 4G and Corporate Governance Statement

August 25, 2026

Notification regarding unquoted securities - NUZ

August 24, 2026

Elanco representative appointed as Neurizon Board Observer

August 12, 2026

Neurizon Completes Initial Drawdown under R&D Facility

August 10, 2026

Neurizon Enters Strategic R&D Financing Facility

July 31, 2026

Appendix 4C & Quarterly Update

July 31, 2026

Melbourne investor briefing presentation

July 28, 2026

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

July 16, 2026

HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27

July 16, 2026

Neurizon executes long-term supply agreement with Elanco

June 16, 2026

HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

June 11, 2026

HEALEY ALS Platform Trial Regimen I expands to 240 participants

May 27, 2026

HEALEY ALS Trial Regimen I Expands to 240 Participants

May 26, 2026

Ethics Approval Received for NUZ-001 Oral Liquid P1 Study

May 12, 2026

Placement of Entitlement Offer Shortfall

April 15, 2026

NUZ-001 Data Shows Multi-Pathway Protein Clearance

March 31, 2026

Neurizon announces leadership transition

March 15, 2026

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

February 26, 2026

Neurizon Initiates Dosing in HEALEY ALS Platform Trial

February 25, 2026

Appendix 4D - Half-year Financial Report - 31 December 2025

February 24, 2026

Appendix 4C & Quarterly Update

January 29, 2026

Neurizon secures $6million R&D Tax Incentive Rebate

January 29, 2026

Neurizon Completes Entitlement Offer

January 26, 2026

Older news releases →

Decks

The 5 newest of 22 decks. Every deck is listed under its year.